A Sampling of Highlights from the Literature

What We're Reading| April 02 2024 A Sampling of Highlights from the Literature: Article Recommendations from Our Deputy and Senior Editors Author & Article Information Online ISSN: 2326-6074 Print ISSN: 2326-6066 ©2024 American Association for Cancer Research2024American Association for Cancer Research Cancer Immunol Res (2024) 12 (4): 381. https://doi.org/10.1158/2326-6066.CIR-12-4-WWR Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn Email Tools Icon Tools Get Permissions Cite Icon Cite Search Site Article Versions Icon Versions Version of Record April 2 2024 Citation A Sampling of Highlights from the Literature: Article Recommendations from Our Deputy and Senior Editors. Cancer Immunol Res 1 April 2024; 12 (4): 381. https://doi.org/10.1158/2326-6066.CIR-12-4-WWR Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest Search Advanced Search Harnessing a cutaneous T-cell lymphoma mutation enhances efficacy of T-cell therapy (from Nephron via Wikimedia Commons). The efficacy of adoptive T-cell therapy is often limited by poor in vivo persistence and function. Hypothesizing that mutations underlying human T-cell cancers might suggest ways to improve the fitness of therapeutic T cells, Garcia et al. screened the effects of 71 such mutations on in vitro and in vivo T-cell phenotypes. A CARD11–PIK3R3 gene fusion was one of the mutations identified for further analysis. CARD11–PIK3R3 expression in human and mouse chimeric-antigen receptor (CAR) T cells and T-cell receptor (TCR) T cells improves their therapeutic efficacy in preclinical models without signs of malignant transformation, highlighting the potential of this approach to identify ways to improve the efficacy of adoptive T-cell therapy. Garcia J, ..., Choi J. Nature 2024 February 7;626,626–634. SMARCAL1 is a dual regulator of tumor immune evasion (Emilian Robert... You do not currently have access to this content.